Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
  • Policy / Pricing

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

KFF Medicare

The private plans that offer the Medicare Part D benefit - stand-alone drug plans and Medicare Advantage drug plans - are increasingly are competing on uneven terms, in part because the payment system

Read full story

pharminent June 11, 2026 (Last updated: June 19, 2026)

KFF Medicare

The private plans that offer the Medicare Part D benefit – stand-alone drug plans and Medicare Advantage drug plans – are increasingly are competing on uneven terms, in part because the payment system

Read full story

Post navigation

Previous: Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
Next: China’s NMPA approves Akeso’s gumokimab for plaque psoriasis

Related Stories

  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Policy / Pricing

Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain

pharminent August 13, 2026
  • Policy / Pricing

Trump signs order that nearly halves childhood immunisation coverage

pharminent August 11, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.